Our top pick for
Electromed Inc is a medical devices business based in the US. Electromed shares (ELMD) are listed on the NYSE MKT and all prices are listed in US Dollars. Electromed employs 132 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$11.01|
|52-week range||$8.11 - $13.85|
|50-day moving average||$12.09|
|200-day moving average||$11.11|
|Wall St. target price||$18.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.27|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||2.23%|
|1 month (2021-09-21)||-12.96%|
|3 months (2021-07-21)||-5.98%|
|6 months (2021-04-21)||6.17%|
|1 year (2020-10-21)||20.72%|
|2 years (2019-10-21)||60.73%|
|3 years (2018-10-19)||65.07%|
|5 years (2016-10-21)||146.86%|
Valuing Electromed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Electromed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Electromed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 41x. In other words, Electromed shares trade at around 41x recent earnings.
Electromed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.8 million.
The EBITDA is a measure of a Electromed's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$35.8 million|
|Operating margin TTM||8.78%|
|Gross profit TTM||$27.3 million|
|Return on assets TTM||5.58%|
|Return on equity TTM||7.54%|
|Market capitalisation||$94.2 million|
TTM: trailing 12 months
There are currently 70,512 Electromed shares held short by investors – that's known as Electromed's "short interest". This figure is 19.2% down from 87,219 last month.
There are a few different ways that this level of interest in shorting Electromed shares can be evaluated.
Electromed's "short interest ratio" (SIR) is the quantity of Electromed shares currently shorted divided by the average quantity of Electromed shares traded daily (recently around 19478.453038674). Electromed's SIR currently stands at 3.62. In other words for every 100,000 Electromed shares traded daily on the market, roughly 3620 shares are currently held short.
However Electromed's short interest can also be evaluated against the total number of Electromed shares, or, against the total number of tradable Electromed shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Electromed's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Electromed shares in existence, roughly 10 shares are currently held short) or 0.011% of the tradable shares (for every 100,000 tradable Electromed shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Electromed.
Find out more about how you can short Electromed stock.
We're not expecting Electromed to pay a dividend over the next 12 months.
Over the last 12 months, Electromed's shares have ranged in value from as little as $8.11 up to $13.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Electromed's is 0.6989. This would suggest that Electromed's shares are less volatile than average (for this exchange).
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.